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Abstract
Skeletal muscle nNOSm (neuronal nitric oxide synthase mu) localizes to the sarcolemma through interaction with the
dystrophin-associated glycoprotein (DAG) complex, where it synthesizes nitric oxide (NO). Disruption of the DAG complex
occurs in dystrophinopathies and sarcoglycanopathies, two genetically distinct classes of muscular dystrophy characterized
by progressive loss of muscle mass, muscle weakness and increased fatigability. DAG complex instability leads to
mislocalization and downregulation of nNOSm; but this is thought to play a minor role in disease pathogenesis. This view
persists without knowledge of the role of nNOS in skeletal muscle contractile function in vivo and has influenced gene
therapy approaches to dystrophinopathy, the majority of which do not restore sarcolemmal nNOSm. We address this
knowledge gap by evaluating skeletal muscle function in nNOS knockout (KN1) mice using an in situ approach, in which the
muscle is maintained in its normal physiological environment. nNOS-deficiency caused reductions in skeletal muscle bulk
and maximum tetanic force production in male mice only. Furthermore, nNOS-deficient muscles from both male and female
mice exhibited increased susceptibility to contraction-induced fatigue. These data suggest that aberrant nNOSm signaling
can negatively impact three important clinical features of dystrophinopathies and sarcoglycanopathies: maintenance of
muscle bulk, force generation and fatigability. Our study suggests that restoration of sarcolemmal nNOSm expression in
dystrophic muscles may be more important than previously appreciated and that it should be a feature of any fully effective
gene therapy-based intervention.
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Introduction
Nitric oxide (NO) is a versatile signaling molecule in skeletal
muscle and is synthesized from oxygen and L-arginine by muscle-
specific neuronal nitricoxidesynthasemu(nNOSm)[1,2].Functions
of NO in muscle include: attenuation of muscle force generation
and regulation of appropriate blood and oxygen delivery to active
muscles during exercise [1,3–7]. However in vitro studies of the role
of nitric oxide in contractile function of excised muscles in perfusion
baths have generated conflicting results. NO has been reported to
increase force-generating capacity of skeletal muscle in some studies
and decrease it in others [1,3–5]. This has led to questioning of the
physiological relevance of these in vitro studies [5]. These data
suggest that the effects of nNOS on the force-generating capacity of
muscle in vivo remain to be determined.
Particular interest in nNOSm function in skeletal muscle arises
from studies of human muscular dystrophies. nNOSm is localized to
the sarcolemma by interaction with the dystrophin-associated
glycoprotein(DAG) complex [8,9]. Disruption of the DAG complex
results in decreased nNOSm expression and aberrant localization.
DAG complex disruption occurs in several distinct dystrophies,
includingDuchenne Muscular Dystrophy(DMD), Becker Muscular
Dystrophy and Limb Girdle Muscular Dystrophies (LGMD) 2C,
2D and 2E [8,10,11]. These muscle diseases vary in severity and are
characterized by progressive loss of muscle bulk, weakness and
increased susceptibility to fatigue. Each disease is characterized by
defects in nNOSm expression and/or targeting. Indeed, DMD
patients exhibit defective inhibition of vasoconstriction during
exercise causing functional muscle ischemia that may exacerbate
dystrophic muscle damage[12,13]. These studies suggest that loss of
nNOSm may contribute to disease pathogenesis.
Although aberrant nNOSm localization and expression is a
feature of the pathology of DMD, BMD and several LGMDs, it is
not known whether the loss of nNOSm can cause contractile deficits
in normal or dystrophic muscle in vivo. Indeed, in vitro studies of NO
regulation of muscle contractility suggest that nNOSm-deficiency
may actually enhance the force generating capacity of skeletal
muscle [3,4]. This thinking has influenced the development of gene-
therapy based therapeutic approaches to treating dystrophin-
deficient muscles of DMD patients. Viral-mediated delivery of
micro- or mini-dystrophin constructs substantially improves dystro-
phic pathology without restoring nNOSm expression at the
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is a significant limitation of the gene-therapy-based approach
remains to be established. It could be a significant limitation if
nNOSm-deficient skeletal muscles exhibit functional deficits in vivo.
In order to determine if the absence of nNOSm negatively
impacts skeletal muscle function, we evaluated the force-generating
capacity in situ of tibialis anterior (TA) muscles from nNOS
knockout (KN1) mice. Given the reported effects of nNOSm on
blood supply during exercise, it was important to use an in situ
approach where the TA muscle was maintained in the most
physiologically relevant state with normal vascularization. Unex-
pectedly, nNOSm-deficient muscles from male mice were smaller in
mass and generated significantly lower maximum isometric force
compared with littermate controls. Moreover, muscles from both
male and female mice lacking nNOSm show increased susceptibility
to fatigue compared with controls. In contrast to previous in vitro
studies, our data suggest that nNOSm-deficiency results in reduced
force-generating capacity and that NO is necessary for sustained
muscle contractility. These data also suggest the possibility that
mini- and micro-dystrophins capable of restoring sarcolemmal
nNOSm expression may be more effective at reversing the
functional deficits of dystrophic skeletal muscle. The combination
of reduced bulk and impaired contractile function lead us to
conclude that nNOSm-deficient muscles are myopathic and that
aberrant nNOSm expression could contribute to functional deficits,
especially increased susceptibility to fatigue, in DMD, BMD and
LGMD 2C, 2D and 2E. We propose that the NOS1 gene be
considered a novel candidate for skeletal muscle myopathies.
Results
Sex-Specific Decrease in Skeletal Muscle Bulk of nNOS-
Deficient Mice
Prima facie, the most striking phenotypic characteristic of the
nNOS mutant KN1 mice was the reduced body mass of males.
Wild type males were on average 6 g heavier than their sex- and
age-matched KN1 littermates (Figure 1A). Heterozygous mice
appeared similar to wild type mice (data not shown). The well-
established sexual dimorphism in body weight was evident from
the significantly larger body masses of wild type males relative to
wild type females. In contrast, the absence of nNOS did not
impact the body mass of KN1 females (Figure 1A). Male mice are
unable to achieve normal size in the absence of nNOS.
Since, skeletal muscle mass accounts for approximately 40–50%
of the total body mass of a normal male 8 week old mouse,
reductions in skeletal muscle weightcould account for the decreased
size of the KN1 males. In order to determine the effect of nNOS-
deficiencyon muscle mass,thewetweights oftwohindlimbmuscles,
the tibialis anterior (a predominantly fast twitch muscle) and soleus
muscles (a predominantly slow twitch muscle), were measured. The
masses of both the TA (Figure 1B) and soleus muscles (Figure 1C)
were significantly decreased in male nNOS mutant mice only,
compared with wild type male littermates. Mass reduction occurs in
skeletal muscles with different fiber compositions, and therefore
could reasonably account for the reduced body mass. In contrast, in
female mice, the masses of both TA and soleus muscle were not
significantly affected by the absence of nNOS (Figure 1B and 1C,
respectively). Together, these data suggest the possibility that nNOS
can act as a sex-specific regulator of skeletal muscle mass in mice.
Decreased Maximum Tetanic Force-Generating Capacity
of nNOSm-Deficient Skeletal Muscle
The amount of contractile force or tension a given skeletal
muscle generates is generally proportional to the mass and length
of the muscle itself. Given the reduced TA muscle bulk in male
KN1 mice, we tested whether the maximum tetanic force-
generating capacity of nNOSm-deficient TA muscles was also
decreased (Figure 2). Maximum tetanic force was significantly
Figure 1. Sex-specific reductions in body and skeletal muscle
mass in nNOS-deficient mice. The body masses of 8 week old adult
male (M) and female (F) mice homozygous for the wild type NOS1 allele
(+/+)o rNOS1 null allele (2/2) are shown in A. The body masses of wild
type males are significantly larger (p,0.01) than KN1 littermates and
wild type females (p,0.01) (A). The masses of tibialis anterior (TA)
muscles from 8 week old adult wild type males are significantly larger
(p,0.01) than KN1 male littermates and wild type females (B). The
masses of soleus muscles are similarly affected in nNOS mutant mice
where KN1 male solei are significantly smaller (p,0.05) than male
littermate controls (C). The soleus muscle of wild type males is larger
than that of wild type females (p,0.05). Numbers of animals analyzed:
10–11 wild type males, 11 KN1 males, 10–11 wild type females and 12–
13 KN1 females. Values shown are mean6standard error of the mean
(S.E.M).
doi:10.1371/journal.pone.0003387.g001
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the decreases in muscle mass described above. The maximum
force-generating capacities of KN1 males, wild type females and
KN1 females were not significantly different (Figure 2A). Wild
type male TA muscles generated larger tetanic force than those
from wild type females. In summary, male nNOSm-deficient TA
muscles are significantly weaker than littermate controls.
To investigate whether deficits in force production in male KN1
mice could be accounted for by decreased TA mass, we calculated
specific force (sPo), the maximal tetanic force output normalized
for the cross sectional area of the TA muscle. sPo was not
significantly affected by the absence of muscle nNOSm in either
sex (Figure 2B). These data support the argument that decreased
force generation in male KN1 TA muscles is most likely due to
decreased muscle mass and not to defects in the contractile
apparatus.
nNOS has been reported to regulate the structure and function
of the neuromuscular synapse [15]. In order to evaluate the
possibility that abnormalities in neuromuscular transmission were
contributing to the maximal tetanic force deficit, we evaluated
force-frequency curves from wild type and KN1 control males. No
significant difference between control and wild type males was
found (Figure 2C), suggesting no gross abnormalities in neuro-
muscular transmission. This is consistent with previously published
results where the absence of nNOSm from postsynaptic folds had
only a minor effect on neuromuscular junction transmission [15].
Taken together, the decreased maximum force and unchanged
specific force output suggest that the sex-specific reduction in
maximal tetanic force in nNOSm-deficient muscle is most likely
due to reduced muscle mass.
nNOSm-Deficient Skeletal Muscle Exhibit Increased
Susceptibility to Contraction-Induced Fatigue
We then tested the hyopthesis that nNOS deficiency impacts
sustained force generation during muscle activity, i.e., the absence
of nNOS may decrease resistance to exercise-induced fatigue. In
order to test this possibility, TA muscles from KN1 mice were
subjected to a simulated exercise protocol in situ (see Methods).
Representative data from wild type and KN1 TA muscles are
shown in Figure 3A and the averages are presented in 3B. After
40 s of simulated exercise, nNOSm-deficient muscles begin to show
deficits in force production (Figure 3A). By the end of the exercise
protocol, the force-generating capacity of KN1 muscle had
declined to a significantly lower force plateau (averaging
45.564.4%) compared with littermate controls (57.861.7%),
(Figure 3B). Note that the trace shown exhibited near normal
recovery. These data highlight a marked increase in fatigability of
nNOSm-deficient skeletal muscle. The time taken to fatigue, as
represented by the time constant t, is not significantly different
between nNOSm-deficient TA muscles and controls (Figure 3B).
After a 1 minute recovery period, KN1 muscles remain unable to
generate normal levels of force compared with controls (Figure 3B).
At 5 minutes post-exercise, nNOS-deficient muscles exhibit a full
recovery (Figure 3B). Both male and female KN1 TA muscles
showed similar enhanced susceptibility to exercise-induced fatigue
(data not shown). It is important to note that susceptibility to
fatigue was not simply a consequence of reduced muscle mass. TA
masses from wild type female mice, male KN1 and female KN1
mice did not differ significantly (Figure 1B), but only nNOS-
deficient TAs were more fatigable. These data highlight a novel
role for nNOS in regulating sustained force generation during
muscle activity.
Next, we addressed potential mechanism(s) of decreased fatigue
resistance in nNOSm-deficient skeletal muscle. We hypothesized
Figure 2. Sex-specific decrease in maximum isometric force-
generating capacity in nNOSm-deficient skeletal muscle. Maxi-
mum isometric force output (Po) from TA muscles of 8 week old adult
male (M) and female (F) mice homozygous for the wild type NOS1 allele
(+/+)o ro rNOS1 null allele (2/2) is shown in A. Po was significantly
decreased (p,0.01) in male KN1 TA muscle compared with sex-
matched littermate controls (A). Wild type male mice generated greater
total force than wild type female mice (p,0.01). Maximum tetanic force
output from female TA skeletal muscle was unaffected by the absence
of nNOSm (A). Specific force (sPo), maximal tetanic force output
normalized for the length and mass of the TA muscle, was not
significantly affected by the absence of muscle nNOSm in both males
and females (B). Force-frequency profiles for wild type (black circles)
and KN1 mice (grey squares) are shown in C. Males and females are
pooled into wild type and KN1 groups. There was no difference in the
force-frequency curves between KN1 males and their littermate controls
suggesting no gross abnormalities in neuromuscular transmission.
Numbers of animals analyzed: 15 wild type (8 males and 7 females) and
15 KN1 (7 males and 8 females). Values shown are mean6standard error
of the mean (S.E.M).
doi:10.1371/journal.pone.0003387.g002
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fast twitch fibers and fewer slow twitch fibers. Fast twitch fibers
have a more glycolytic metabolism and thus fatigue more easily
than slow twitch myofibers. A greater proportion of fast twitch
fibers would decrease the time taken for the muscle to reach peak
twitch tension (Pt) and shorten the relaxation phase. The twitch
responses of nNOS-deficient muscles to a single threshold stimulus
are shown in Table 1. Peak twitch force (Pt) was significantly
reduced in KN1 males compared with controls. Despite this
decrease, nNOSm-deficient muscles did not exhibit any intrinsic
weakness, because specific twitch force (sPt,[ P t normalized for
cross sectional area]) did not differ from littermate controls
(Table 1). However, in contrast to male KN1 muscle, Pt was
unaffected by the absence of nNOSm in female mice (Table 1).
KN1 male mice exhibit a sex-specific decrease in Pt, paralleling
the decreased TA muscle mass and maximum isometric force
deficit. The loss of nNOSm from skeletal muscle had no significant
impact on the time to reach peak tension and the time between
maximum and half-maximum force production during the
relaxation phase of the twitch (Table 1). The absence of significant
difference in the time of the contraction and relaxation phase of
the twitch suggest that there is no gross change in the fiber
composition of the TA muscle and argue against a fiber type shift
as a mechanism for the increased fatigability of nNOSm-deficient
muscle.
An alternative possibility was that the decreased resistance to
fatigue in KN1 skeletal muscle was caused by an increase in the
TA muscle’s susceptibility to contraction-induced injury. There-
fore we tested whether nNOSm-deficiency impacts resistance to
contraction-induced injury in situ by subjecting TA muscles to a
series of consecutive lengthening contractions of progressively
increasing strain (Figure 4). We observed no significant difference
in resistance to contraction-induced injury between wild type and
nNOSm-deficient TA muscles over a wide range of strains
Figure 3. nNOSm-deficient skeletal muscle exhibits decreased
resistance to exercise-induced fatigue. To simulate exercise, TA
muscles were maximally stimulated every 2 s for 4 minutes (fatigue
period). Force recovery was measured after 1 minute and 5 minutes of
rest following the conclusion of the fatigue period. Representative data
are shown for wild type (black boxes) and KN1 (grey triangles) and are
fitted with exponential decay curves (black for wild type and grey for
KN1) (A). Both male and female KN1 mice showed similar patterns of
fatigue. During 4 minutes of repeated contraction, nNOSm-deficient
skeletal muscles did not sustain control levels of force (A). Force
generation capacity of KN1 mice declined to a significantly lower force
plateau (p,0.05) than wild type controls (B). The time taken to fatigue
represented by the time constant t, was not significantly different
between wild type and KN1 mice (B). After 1 minute of rest, nNOS-
deficient TA muscles did not recover to the same extent as wild type TA
muscle (p,0.05). However, after 5 minutes of rest, the force-generating
capacity of nNOS-deficient muscles was fully recovered (B). Numbers of
animals analyzed: 13 wild type (7 males and 6 females) and 13 KN1 (5
males and 8 females) mice. Values shown in B are mean6standard error
of the mean (S.E.M).
doi:10.1371/journal.pone.0003387.g003
Table 1. Twitch Properties of nNOSm-Deficient Skeletal
Muscle Fibers.
Male Female
Wild Type KN1 Wild Type KN1
Pt (mN) 486622 376617{ 373619# 350613
TPT (ms) 17.861.5 20.261 15.760.6 19.260.9
HRT (ms) 19.561.4 22.661.1 19.161.7 22.761.6
sPt (kNm
22) 79.463.2 80.763 77.163.6 78.462.9
Pt is twitch force. TPT is the time taken to reach peak tension during the
contraction phase of the twitch. HRT is the time between maximum and half-
maximum force generation during the relaxation phase of the twitch. sPt is
specific twitch force. Mean values6SEM are shown. { p,0.01, for comparison
between wild type and KN1 males. # p,0.01, for comparison between wild
type males and females.
doi:10.1371/journal.pone.0003387.t001
Figure 4. nNOSm-deficiency does not affect the susceptibility of
the TA to contraction-induced injury. Contraction-induced injury
was produced by subjecting TA muscles to a series of consecutive
lengthening contractions of progressively increasing strain. Strain is the
percentage increase in length beyond optimal muscle length Lo.
Contractile function is expressed as normalized force (force/initial force
or P/Pi). The susceptibility to contraction-induced injury for wild type
(black squares) and nNOS-deficient (grey diamonds) TA muscles are
shown. There was no significant difference between controls and KN1
littermates. Numbers of animals analyzed: 14 wild type (8 males and 6
females) and 11 KN1 (5 males and 6 females) mice. Values shown are
mean6standard error of the mean (S.E.M).
doi:10.1371/journal.pone.0003387.g004
Myopathy in nNOS Null Mice
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susceptibility of the TA to contraction-induced injury. The
impaired performance of nNOSm-deficient skeletal muscle during
exercise is unlikely to be due to an increased predisposition to
contraction-induced injury.
Discussion
This study provides surprising new insights into nNOSm
function in skeletal muscle in vivo. nNOSm-deficiency significantly
reduces skeletal muscle mass, maximum tetanic force output and
fatigue resistance; therefore qualifying the skeletal muscles of KN1
mice as myopathic. Unexpectedly, myopathy is most severe in
nNOS-deficient male mice, because female mice exhibit increased
fatigability only. Despite the NOS1 gene being localized to murine
autosome five, and not on a sex chromosome, the impact of nNOS
on skeletal muscle is mediated by unknown sex-specific mecha-
nisms. This emphasizes the importance of considering gender
when experimentally assessing nNOS function. Our data suggest
that nNOSm is an important regulator of skeletal muscle size and
contractile performance.
One of the key features of nNOSm-deficient skeletal muscle is
increased susceptibility to fatigue, arguably the most significant
new finding of the present study. The force generated by nNOSm-
deficient muscles during simulated exercise plateaus at a
significantly lower level than controls (Figure 3B). Recovery
appears to occur more gradually in KN1 mice; however there is
full restoration of force-generating capacity after a five minute rest
period. In order to address potential mechanisms of decreased
resistance to fatigue in KN1 mice, we looked for functional
evidence of increased numbers of fast twitch fibers in KN1 TA
muscle (Table 1). Fast twitch fibers are more easily fatigued than
slow twitch fibers. Contraction and relaxation times of single
muscle twitches were unaffected by the absence of nNOSm,
arguing that increased fatigability was not due to alterations in the
ratio of fast to slow twitch fibers. nNOSm-derived NO plays an
important role in maintaining normal blood supply during exercise
by overriding a-adrenergic receptor-mediated vasoconstriction
[6,7]. Impaired blood and oxygen delivery to the vascular beds of
active muscles can result in repeated muscle exposure to functional
ischemia [12]. Therefore we speculate that decreased muscle
oxygenation could account, at least in part, for the susceptibility to
fatigue of nNOSm-deficient TA muscles. Additional evidence to
support this possibility comes from dog studies in vivo where
pharmacological inhibition of nitric oxide synthesis was proposed
to cause fatigue by mismatching blood supply with demand in
contracting skeletal muscles [18]. Muscle fatigue is a complex
physiological process that can occur by many different mecha-
nisms, further studies are required to address the exact
mechanism(s) by which nNOS-deficiency results in increased
susceptibility of skeletal muscle to fatigue. At present, nNOSm
deficiency does not appear to increase fatigability by significantly
altering TA muscle fiber type composition, but may do so through
impaired vasoregulatory mechanisms.
NO has been previously suggested to be an inhibitor of the force-
generating capacity of skeletal muscle. In in vitro bath studies on
excised muscles, the pharmacological inhibition of NOS results in
greater force output [3,4]. Thus, nitric oxide is widely understood to
act as an inhibitor or attenuator of muscle contractility. However,
these data are not consistent with our findings in vivo. We find that
the absence of nNOSm is associated with decreased maximal force-
generating capacity in males. This is most likely due to decreased
muscle mass and not due to defects in the contractile apparatus
function; because specific force (sPo) was unchanged (Figure 2B).
Similarly, the mass and force-generating capacity of female TA are
unaffected by the absence of nNOSm; therefore the differences
between male and female force maximal force generation are likely
due to differential impact on muscle mass. Also, inconsistent with
the thesis that NO attenuates muscle function, we found that force
frequency curves were unaffected by the loss of nNOSm and the
maximum force-generating properties of female muscle were
unaffected by the loss of nNOS. In our view, the most likely
explanation of the conflicting reports of the impact of NO on
contractility is provided by the different experimental approaches
employed. We used an in situ approach where the TA muscle is kept
in the most physiologically relevant environment possible, within
normal physiological temperature range, with intact motor neuron
innervation and vasculature [17]. This is very important for
evaluating nNOSm function in muscle due to its known vasor-
egulatory role. We also circumvented the limitations of pharmaco-
logical inhibition of NOS by using the KN1 mouse to specifically
inactivate nNOS. Our view is supported by a recent study
questioning the physiological relevance of studies designed to
address the role of NO in muscle contraction that were conducted
on excised muscles in physiological baths in vitro [5]. It was reported
that regulation of muscle contractile function by nNOSm depended
dramatically on oxygen concentration [5]. At non-physiological
oxygen concentrations, such as those found in excised in vitro muscle
preparations, NO inhibited muscle contractility. Conversely, at low
physiological oxygen tensions resembling those found in muscle
tissue,NOincreasedtheforce-generatingcapacityofskeletalmuscle
[5]. Our finding that nNOS deficiency results in force loss in situ is
consistent with in vitro studies performed under physiological oxygen
conditions. Therefore, our in situ methods presumably maintain
more physiologically relevant concentrations of oxygen in muscle
tissue. In summary, these data suggest that nNOS-derived NO is
necessary for maximal force-generating capacity of muscle in vivo
and that nNOS plays an important role in the contractile
performance of skeletal muscle. Furthermore, these results are
consistent with a role of both oxygen and NO in coordinated
regulation of the force-generating capacity of skeletal muscle.
The impact of nNOS-deficiency on muscle contractility has
implications for two classes of muscle disease: metabolic
myopathies and muscular dystrophies. Skeletal muscle fatigue is
a common cause of weakness in human myopathies that result
from congenital defects in energy metabolism [18]. These muscle
diseases often elude diagnosis since symptoms occur predominant-
ly or exclusively during exercise. Often symptoms are simply
attributed to a lack of fitness [18]. Since the skeletal muscle
phenotype of KN1 mice is consistent with that of human
metabolic myopathies, the NOS1 gene may be a novel candidate
gene for this class of skeletal muscle disease. The deficiencies in
nNOSm-deficient skeletal muscle are also especially relevant to two
types of muscular dystrophy, dystrophinopathies (DMD and
BMD) and sarcoglycanopathies (LGMD 2C, LGMD 2D and
LGMD 2E), two genetically distinct classes of muscular dystrophy
where skeletal muscle nNOSm expression and localization is
dysregulated as a secondary consequence of the disruption of the
DAG complex [8,10,11,19]. nNOSm protein expression is
undetectable in cytoplasmic or plasma membrane fractions from
DMD patient biopsies [19]. Aberrant nNOSm activity may
contribute to the pathogenesis in DMD and LGMD by impairing
blood flow in active muscles resulting in ischemia [6,7]. Indeed,
increased NO bioavailability in mouse models of DMD (mdx mice)
and LGMD2D (a-sarcoglycan null mice) substantially improves
the pathology of dystrophic skeletal muscle tissue [20–22]. Our
data suggest that specific characteristics of dystrophic pathology,
including the inability to maintain muscle bulk, inherent muscle
Myopathy in nNOS Null Mice
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in part, to defects in nNOS signaling. Our data also raise the
intriguing possibility that loss of nNOSm is more detrimental to
muscle function in male patients than in female patients.
The pervasive inherent weakness of dystrophin-deficient muscle
is due to both increased susceptibility to injury by lengthening
contraction and fatigue [23–26]. The impaired performance of a-
and c-sarcoglycan-deficient skeletal muscles is also due, at least in
part, to increased susceptibility to fatigue, but not contraction-
induced injury [26–28]. Our data argue against a role for aberrant
nNOSm expression contributing to increased susceptibility to
contraction-induced injury, but do suggest the possibility that
dysregulation of nNOS signaling provides a mechanism for muscle
activity-induced fatigue, a contributing factor to the impaired
contractile performance of human and murine dystrophic muscle
[23–28]. These findings make nNOS signaling pathways relevant
to therapeutic approaches to muscular dystrophy.
Therapeutic approaches to treating muscular dystrophies must
address the progressive loss of muscle mass and extreme muscle
weakness. The ideal method to do this is to replace the defective
gene with a wild type copy using gene or cell therapy based
approaches [14]. However, in the case of gene therapy of DMD,
this is not currently possible because dystrophin is too large to be
packaged into adeno-associated viral vectors. This has led to
replacement strategies that involve viral vector-mediated delivery
of truncated ‘‘designer dystrophin’’ constructs in DMD [14].
These micro- and mini-dystrophins cause substantial improve-
ments, but do not fully restore the dystrophic pathology and
muscle function in mdx mice. Importantly, these mutant dystro-
phins do not restore nNOSm [14]. Although the substantial
improvement of dystrophic muscle function by mini- and micro-
dystrophin suggests a minor role for nNOS in mdx pathology; the
evaluation of fatigue is rarely, if ever, assayed in treated muscles
despite reports of fatigue in both mice and patients [23–25].
Furthermore, mdx mice exhibit increased muscle mass, in contrast
to Duchenne patients who suffer progressive loss of muscle mass.
The present study suggests that the ability to restore nNOSm
would likely confer additional important functionality to the
designer dystrophins. These data strongly argue that the
restoration of sarcolemmal nNOSm in dystrophic muscle may be




tmplh/J mice purchased from The Jackson Labora-
tory, ME, USA were used to establish a colony. These mice are
commonly known as nNOS knockout or KN1 mice and were
generated by targeted disruption of exon 2 of the NOS1 gene [29].
Exon 2 encodes the PDZ domain of nNOSa and muscle–specific
nNOSm; therefore, the skeletal muscles of KN1 mice lack nNOSm.
All comparisons are made between sex- and age-matched littermates.
In Situ Contractile Function Analyses
All experimental procedures performed on mice were approved
by the Institutional Animal Care and Use Committee of the
University of Washington. We performed in situ analysis of TA
muscle function with modifications as described previously [17].
This approach allows for measurement of contractile properties
without removing the muscle from its natural environment,
thereby maintaining normal vasoregulation and innervation. Eight
week old mice were anesthetized with intraperitoneal injections of
2,2,2, tribromoethanol (Sigma, St Louis, MO). Mouse hindlimbs
were shaved and the distal TA tendon of the tibialis anterior (TA)
muscle was surgically isolated via a skin incision on the anterior
surface of the lower hindlimb. The mouse was positioned on a
37uC heated platform in order to restrain the knee joint and the
distal tendon was attached to the lever arm of a servomotor
(Model 305B-LR, Aurora Scientific, ON, Canada). The exposed
surface of the muscle was kept moist by frequent application of
prewarmed isotonic saline. The TA muscle was stimulated by
electrical trigger of the peroneal nerve using two needle electrodes.
The muscle was adjusted to an optimum length (Lo) that produced
the maximum twitch force (Pt). Then, the time to reach peak
tension (TPT) during the contraction phase of the twitch, and the
half-relaxation time (HRT), the time between maximum and half-
maximum force during the relaxation phase of the twitch were
recorded. While held at Lo the TA was stimulated every two
minutes at increasing frequencies (5 to 200 Hz) to generate force-
frequency curves. Maximal tetanic force (Po) generation was
typically achieved at 200 Hz. After the completion of testing, both
Lo and TA mass were recorded and used to normalize Pt and Po
for TA muscle size and calculate specific twitch (sPt) or specific
tetanic (sPo) force. The first hindlimb was used for testing
resistance to exercise-induced fatigue, while the second was used
to test susceptibility to contraction-induced injury.
Resistance to Exercise-Induced Fatigue
To test the capacity of muscle to sustain force output, TA muscles
were subjected to a series of repeated contractions to simulate
exercise and cause fatigue. Muscles were subject to maximal
stimulation (40 V, 200 Hz) at 2 s intervals for 4 minutes. Maximum
isometric force production was recorded every 2 s. Recovery from
fatigue was assessed by recording Po at 1 minute and 5 minutes after
the completion of the fatigue period. Exponential curves (y=Ae
2x/t
where A is the initial force (mN), x is time (s) and t is the time
constant) were fitted to the 4 minute fatigue period with Igor Pro 5
software (Wavemetrics, OR). The time constant t (reflecting the
timecourse of fatigue in seconds where a larger t value represents a
slower rate of fatigue) and the force plateau (the asymptote of the
exponential curve) were calculated from these curves.
Contraction-Induced Injury
The resistance of muscles to contraction-induced injury was
assessed by subjecting TA muscles to a series of consecutive
lengthening contractions of progressively increased strain. Strain is
the percentage increase in length beyond the optimal muscle
length Lo. Muscles were maximally stimulated (4 V, 200 Hz) for
150 ms at fixed length to achieve maximal isometric tension,
immediately followed by 200 ms of stimulation during the
application of a length change ranging from 0 to 45% beyond
Lo. Strain was applied at the rate of 2 fiber lengths/s. Lengthening
contractions were performed at 30 s intervals to minimize the
impact of fatigue on force-generating capacity. The maximum
tetanic force generated immediately prior to the initiation of the
subsequent lengthening contraction was recorded and normalized.
At the conclusion of contractile function analysis, animals were
sacrificed and the tibialis anterior and soleus muscles were rapidly
excised and weighed.
Statistical Analyses
The number of animals of each sex and genotype analyzed for
each experimental condition are given in the figure legends. All
values are reported as mean6SEM. Two way univariate analysis
of variance (ANOVA) was used to determine the statistical
significance of the effects of gender and genotype on experimental
measures using SPSS software (SPSS Inc.). For all other
comparisons, values were compared using unpaired Student’s t-
Myopathy in nNOS Null Mice
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were considered significant.
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